nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—SLCO1A2—Spironolactone—dilated cardiomyopathy	0.438	0.518	CbGbCtD
Mirabegron—ALB—Furosemide—dilated cardiomyopathy	0.154	0.183	CbGbCtD
Mirabegron—ABCB1—Lisinopril—dilated cardiomyopathy	0.134	0.159	CbGbCtD
Mirabegron—ABCB1—Spironolactone—dilated cardiomyopathy	0.118	0.14	CbGbCtD
Mirabegron—Breast cancer—Spironolactone—dilated cardiomyopathy	0.0151	0.128	CcSEcCtD
Mirabegron—Propafenone—SCN5A—dilated cardiomyopathy	0.00375	0.27	CrCbGaD
Mirabegron—Nephrolithiasis—Furosemide—dilated cardiomyopathy	0.00374	0.0315	CcSEcCtD
Mirabegron—Gastritis—Spironolactone—dilated cardiomyopathy	0.00355	0.0299	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00306	0.0258	CcSEcCtD
Mirabegron—Arbutamine—ADRB1—dilated cardiomyopathy	0.00275	0.198	CrCbGaD
Mirabegron—Bladder pain—Furosemide—dilated cardiomyopathy	0.00272	0.0229	CcSEcCtD
Mirabegron—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00262	0.0221	CcSEcCtD
Mirabegron—Vascular purpura—Furosemide—dilated cardiomyopathy	0.00244	0.0206	CcSEcCtD
Mirabegron—Arbutamine—ADRB2—dilated cardiomyopathy	0.00231	0.166	CrCbGaD
Mirabegron—Purpura—Furosemide—dilated cardiomyopathy	0.00226	0.0191	CcSEcCtD
Mirabegron—ADRB3—Adrenoceptors—ADRB1—dilated cardiomyopathy	0.00223	0.0982	CbGpPWpGaD
Mirabegron—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.0022	0.0186	CcSEcCtD
Mirabegron—Cystitis—Lisinopril—dilated cardiomyopathy	0.00218	0.0184	CcSEcCtD
Mirabegron—Urinary retention—Furosemide—dilated cardiomyopathy	0.00207	0.0175	CcSEcCtD
Mirabegron—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00204	0.0172	CcSEcCtD
Mirabegron—Labetalol—ADRB1—dilated cardiomyopathy	0.00195	0.14	CrCbGaD
Mirabegron—Abdominal distension—Furosemide—dilated cardiomyopathy	0.0019	0.016	CcSEcCtD
Mirabegron—ADRB3—Adrenoceptors—ADRB2—dilated cardiomyopathy	0.00181	0.0796	CbGpPWpGaD
Mirabegron—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00173	0.0146	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.0017	0.0143	CcSEcCtD
Mirabegron—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00167	0.0141	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00167	0.0141	CcSEcCtD
Mirabegron—Labetalol—ADRB2—dilated cardiomyopathy	0.00164	0.118	CrCbGaD
Mirabegron—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00164	0.0138	CcSEcCtD
Mirabegron—Urticaria—Spironolactone—dilated cardiomyopathy	0.00157	0.0132	CcSEcCtD
Mirabegron—Propafenone—ADRB1—dilated cardiomyopathy	0.00149	0.107	CrCbGaD
Mirabegron—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00149	0.0126	CcSEcCtD
Mirabegron—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00148	0.0125	CcSEcCtD
Mirabegron—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00148	0.0125	CcSEcCtD
Mirabegron—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00146	0.0123	CcSEcCtD
Mirabegron—Gastritis—Lisinopril—dilated cardiomyopathy	0.00145	0.0122	CcSEcCtD
Mirabegron—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00143	0.012	CcSEcCtD
Mirabegron—Influenza—Lisinopril—dilated cardiomyopathy	0.00141	0.0119	CcSEcCtD
Mirabegron—Eye disorder—Furosemide—dilated cardiomyopathy	0.00141	0.0119	CcSEcCtD
Mirabegron—Pruritus—Spironolactone—dilated cardiomyopathy	0.00139	0.0118	CcSEcCtD
Mirabegron—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00135	0.0114	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00131	0.0111	CcSEcCtD
Mirabegron—Dizziness—Spironolactone—dilated cardiomyopathy	0.0013	0.011	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00125	0.0105	CcSEcCtD
Mirabegron—Rash—Spironolactone—dilated cardiomyopathy	0.00124	0.0105	CcSEcCtD
Mirabegron—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00124	0.0105	CcSEcCtD
Mirabegron—Vision blurred—Furosemide—dilated cardiomyopathy	0.00124	0.0104	CcSEcCtD
Mirabegron—Headache—Spironolactone—dilated cardiomyopathy	0.00123	0.0104	CcSEcCtD
Mirabegron—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00123	0.0103	CcSEcCtD
Mirabegron—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00118	0.00998	CcSEcCtD
Mirabegron—Nausea—Spironolactone—dilated cardiomyopathy	0.00117	0.00987	CcSEcCtD
Mirabegron—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00114	0.00957	CcSEcCtD
Mirabegron—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00112	0.00943	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00111	0.00937	CcSEcCtD
Mirabegron—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00111	0.00936	CcSEcCtD
Mirabegron—Dry mouth—Furosemide—dilated cardiomyopathy	0.00109	0.00922	CcSEcCtD
Mirabegron—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00107	0.00903	CcSEcCtD
Mirabegron—Skin disorder—Furosemide—dilated cardiomyopathy	0.00104	0.00878	CcSEcCtD
Mirabegron—Back pain—Lisinopril—dilated cardiomyopathy	0.000953	0.00804	CcSEcCtD
Mirabegron—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000929	0.00783	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000926	0.0078	CcSEcCtD
Mirabegron—Fatigue—Furosemide—dilated cardiomyopathy	0.000924	0.00779	CcSEcCtD
Mirabegron—Constipation—Furosemide—dilated cardiomyopathy	0.000917	0.00773	CcSEcCtD
Mirabegron—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000877	0.00739	CcSEcCtD
Mirabegron—Palpitations—Lisinopril—dilated cardiomyopathy	0.000871	0.00734	CcSEcCtD
Mirabegron—Urticaria—Furosemide—dilated cardiomyopathy	0.000852	0.00718	CcSEcCtD
Mirabegron—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000848	0.00715	CcSEcCtD
Mirabegron—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000839	0.00708	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000833	0.00703	CcSEcCtD
Mirabegron—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000821	0.00692	CcSEcCtD
Mirabegron—Infection—Lisinopril—dilated cardiomyopathy	0.000799	0.00674	CcSEcCtD
Mirabegron—ADRB3—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00079	0.0347	CbGpPWpGaD
Mirabegron—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000785	0.00662	CcSEcCtD
Mirabegron—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000781	0.00659	CcSEcCtD
Mirabegron—Asthenia—Furosemide—dilated cardiomyopathy	0.000769	0.00649	CcSEcCtD
Mirabegron—Pruritus—Furosemide—dilated cardiomyopathy	0.000759	0.0064	CcSEcCtD
Mirabegron—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000734	0.00619	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000733	0.00618	CcSEcCtD
Mirabegron—Dizziness—Furosemide—dilated cardiomyopathy	0.000709	0.00598	CcSEcCtD
Mirabegron—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000708	0.00597	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000695	0.00586	CcSEcCtD
Mirabegron—Fatigue—Lisinopril—dilated cardiomyopathy	0.000694	0.00585	CcSEcCtD
Mirabegron—Constipation—Lisinopril—dilated cardiomyopathy	0.000688	0.0058	CcSEcCtD
Mirabegron—Rash—Furosemide—dilated cardiomyopathy	0.000676	0.0057	CcSEcCtD
Mirabegron—Dermatitis—Furosemide—dilated cardiomyopathy	0.000675	0.00569	CcSEcCtD
Mirabegron—Headache—Furosemide—dilated cardiomyopathy	0.000672	0.00566	CcSEcCtD
Mirabegron—ADRB3—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.000664	0.0292	CbGpPWpGaD
Mirabegron—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000658	0.00555	CcSEcCtD
Mirabegron—ADRB3—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00064	0.0282	CbGpPWpGaD
Mirabegron—Urticaria—Lisinopril—dilated cardiomyopathy	0.000639	0.00539	CcSEcCtD
Mirabegron—Nausea—Furosemide—dilated cardiomyopathy	0.000637	0.00537	CcSEcCtD
Mirabegron—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000636	0.00536	CcSEcCtD
Mirabegron—BCHE—Glycerophospholipid biosynthesis—TAZ—dilated cardiomyopathy	0.000636	0.028	CbGpPWpGaD
Mirabegron—Asthenia—Lisinopril—dilated cardiomyopathy	0.000577	0.00487	CcSEcCtD
Mirabegron—Pruritus—Lisinopril—dilated cardiomyopathy	0.000569	0.0048	CcSEcCtD
Mirabegron—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00055	0.00464	CcSEcCtD
Mirabegron—ADRB3—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.000538	0.0237	CbGpPWpGaD
Mirabegron—Dizziness—Lisinopril—dilated cardiomyopathy	0.000532	0.00449	CcSEcCtD
Mirabegron—Rash—Lisinopril—dilated cardiomyopathy	0.000507	0.00428	CcSEcCtD
Mirabegron—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000507	0.00427	CcSEcCtD
Mirabegron—Headache—Lisinopril—dilated cardiomyopathy	0.000504	0.00425	CcSEcCtD
Mirabegron—ADRB3—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.0005	0.022	CbGpPWpGaD
Mirabegron—ADRB3—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.000486	0.0214	CbGpPWpGaD
Mirabegron—Nausea—Lisinopril—dilated cardiomyopathy	0.000478	0.00403	CcSEcCtD
Mirabegron—BCHE—Phospholipid metabolism—TAZ—dilated cardiomyopathy	0.000443	0.0195	CbGpPWpGaD
Mirabegron—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.000434	0.0191	CbGpPWpGaD
Mirabegron—ADRB3—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.000403	0.0177	CbGpPWpGaD
Mirabegron—ALB—Platelet degranulation—TTN—dilated cardiomyopathy	0.000289	0.0127	CbGpPWpGaD
Mirabegron—ALB—Response to elevated platelet cytosolic Ca2+—TTN—dilated cardiomyopathy	0.000276	0.0121	CbGpPWpGaD
Mirabegron—ADRB3—G alpha (s) signalling events—ADRB1—dilated cardiomyopathy	0.000274	0.012	CbGpPWpGaD
Mirabegron—CYP2D6—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.000255	0.0112	CbGpPWpGaD
Mirabegron—ALB—Platelet degranulation—ACTN2—dilated cardiomyopathy	0.000251	0.011	CbGpPWpGaD
Mirabegron—ALB—Response to elevated platelet cytosolic Ca2+—ACTN2—dilated cardiomyopathy	0.000239	0.0105	CbGpPWpGaD
Mirabegron—ADRB3—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.000236	0.0104	CbGpPWpGaD
Mirabegron—SLCO1A2—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000224	0.00988	CbGpPWpGaD
Mirabegron—BCHE—Peptide hormone metabolism—ACE—dilated cardiomyopathy	0.000222	0.00977	CbGpPWpGaD
Mirabegron—ADRB3—G alpha (s) signalling events—ADRB2—dilated cardiomyopathy	0.000222	0.00976	CbGpPWpGaD
Mirabegron—BCHE—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.000217	0.00953	CbGpPWpGaD
Mirabegron—ALB—Platelet degranulation—VCL—dilated cardiomyopathy	0.000213	0.00939	CbGpPWpGaD
Mirabegron—ALB—Response to elevated platelet cytosolic Ca2+—VCL—dilated cardiomyopathy	0.000203	0.00895	CbGpPWpGaD
Mirabegron—ADRB3—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.000195	0.00859	CbGpPWpGaD
Mirabegron—ADRB3—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.000192	0.00843	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000173	0.00762	CbGpPWpGaD
Mirabegron—BCHE—Neuronal System—ABCC9—dilated cardiomyopathy	0.000173	0.00762	CbGpPWpGaD
Mirabegron—ADRB3—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000169	0.00745	CbGpPWpGaD
Mirabegron—BCHE—Neuronal System—ACTN2—dilated cardiomyopathy	0.000166	0.0073	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000163	0.00716	CbGpPWpGaD
Mirabegron—ADRB3—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000157	0.00692	CbGpPWpGaD
Mirabegron—ALB—Binding and Uptake of Ligands by Scavenger Receptors—CD36—dilated cardiomyopathy	0.000156	0.00687	CbGpPWpGaD
Mirabegron—ADRB3—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000152	0.00671	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000152	0.00668	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000145	0.00638	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000145	0.00638	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000143	0.00628	CbGpPWpGaD
Mirabegron—ALB—Vitamin B12 Metabolism—SOD2—dilated cardiomyopathy	0.000141	0.00621	CbGpPWpGaD
Mirabegron—BCHE—Peptide hormone metabolism—AGT—dilated cardiomyopathy	0.000141	0.00619	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000135	0.00593	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000131	0.00574	CbGpPWpGaD
Mirabegron—ADRB3—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00013	0.00573	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	0.000128	0.00565	CbGpPWpGaD
Mirabegron—ADRB3—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000123	0.00543	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—ZBTB17—dilated cardiomyopathy	0.000123	0.00543	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—TAZ—dilated cardiomyopathy	0.000123	0.00543	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000123	0.00541	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000117	0.00516	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—SOD2—dilated cardiomyopathy	0.000115	0.00505	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000114	0.00502	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000114	0.00502	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000111	0.00491	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	0.000111	0.0049	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00011	0.00486	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00011	0.00486	CbGpPWpGaD
Mirabegron—ALB—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00011	0.00483	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—GPX1—dilated cardiomyopathy	0.000109	0.00482	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000106	0.00467	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000106	0.00465	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000103	0.00455	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000103	0.00452	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—ADRB1—dilated cardiomyopathy	9.94e-05	0.00437	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	9.47e-05	0.00417	CbGpPWpGaD
Mirabegron—ALB—Platelet degranulation—CD36—dilated cardiomyopathy	9.14e-05	0.00402	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	9.11e-05	0.00401	CbGpPWpGaD
Mirabegron—ALB—Response to elevated platelet cytosolic Ca2+—CD36—dilated cardiomyopathy	8.71e-05	0.00383	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	8.69e-05	0.00383	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	8.67e-05	0.00382	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—AGTR1—dilated cardiomyopathy	8.49e-05	0.00374	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	8.46e-05	0.00372	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	8.06e-05	0.00355	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—ADRB2—dilated cardiomyopathy	8.05e-05	0.00354	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	7.95e-05	0.0035	CbGpPWpGaD
Mirabegron—ADRB3—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	7.85e-05	0.00345	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	7.77e-05	0.00342	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—ANKRD1—dilated cardiomyopathy	7.71e-05	0.00339	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—TAZ—dilated cardiomyopathy	7.25e-05	0.00319	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—ANKRD1—dilated cardiomyopathy	6.76e-05	0.00298	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TTN—dilated cardiomyopathy	6.62e-05	0.00291	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—SDHA—dilated cardiomyopathy	6.55e-05	0.00288	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—TAZ—dilated cardiomyopathy	6.36e-05	0.0028	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	6.24e-05	0.00275	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	6.24e-05	0.00275	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—AGT—dilated cardiomyopathy	5.97e-05	0.00263	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	5.8e-05	0.00255	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—SDHA—dilated cardiomyopathy	5.75e-05	0.00253	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—ACTN2—dilated cardiomyopathy	5.74e-05	0.00253	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	5.73e-05	0.00252	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—AGTR2—dilated cardiomyopathy	5.67e-05	0.00249	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CXCL2—dilated cardiomyopathy	5.67e-05	0.00249	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	5.62e-05	0.00247	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	5.57e-05	0.00245	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	5.57e-05	0.00245	CbGpPWpGaD
Mirabegron—ALB—Vitamin B12 Metabolism—TNF—dilated cardiomyopathy	5.35e-05	0.00235	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CXCR3—dilated cardiomyopathy	5.27e-05	0.00232	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	5.18e-05	0.00228	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—ADRB1—dilated cardiomyopathy	5.1e-05	0.00224	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	5.02e-05	0.00221	CbGpPWpGaD
Mirabegron—BCHE—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	4.93e-05	0.00217	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	4.88e-05	0.00215	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	4.88e-05	0.00215	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—VCL—dilated cardiomyopathy	4.88e-05	0.00215	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—LMNA—dilated cardiomyopathy	4.86e-05	0.00214	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	4.8e-05	0.00211	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	4.55e-05	0.002	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	4.54e-05	0.002	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—AGTR1—dilated cardiomyopathy	4.36e-05	0.00192	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—TNF—dilated cardiomyopathy	4.35e-05	0.00191	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—ACE—dilated cardiomyopathy	4.19e-05	0.00184	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—ADRB2—dilated cardiomyopathy	4.13e-05	0.00182	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	4.05e-05	0.00178	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4e-05	0.00176	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	3.98e-05	0.00175	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.89e-05	0.00171	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	3.84e-05	0.00169	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	3.82e-05	0.00168	CbGpPWpGaD
Mirabegron—BCHE—Neuronal System—RAF1—dilated cardiomyopathy	3.77e-05	0.00166	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PSEN2—dilated cardiomyopathy	3.77e-05	0.00166	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ANKRD1—dilated cardiomyopathy	3.77e-05	0.00166	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	3.76e-05	0.00166	CbGpPWpGaD
Mirabegron—ALB—Metabolism—TAZ—dilated cardiomyopathy	3.54e-05	0.00156	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—RAC1—dilated cardiomyopathy	3.53e-05	0.00156	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.51e-05	0.00154	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.51e-05	0.00154	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	3.46e-05	0.00152	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.42e-05	0.0015	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—AGT—dilated cardiomyopathy	3.38e-05	0.00149	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.35e-05	0.00147	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.35e-05	0.00147	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	3.3e-05	0.00145	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	3.3e-05	0.00145	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—RAC1—dilated cardiomyopathy	3.21e-05	0.00141	CbGpPWpGaD
Mirabegron—ALB—Metabolism—SDHA—dilated cardiomyopathy	3.2e-05	0.00141	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CXCR3—dilated cardiomyopathy	3.11e-05	0.00137	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	3.11e-05	0.00137	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	3.1e-05	0.00137	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.08e-05	0.00135	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—AGT—dilated cardiomyopathy	3.07e-05	0.00135	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.01e-05	0.00133	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	2.92e-05	0.00129	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	2.81e-05	0.00123	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—AGT—dilated cardiomyopathy	2.66e-05	0.00117	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	2.64e-05	0.00116	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.57e-05	0.00113	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	2.53e-05	0.00111	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	2.49e-05	0.0011	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—ITGB1—dilated cardiomyopathy	2.45e-05	0.00108	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.44e-05	0.00107	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.31e-05	0.00102	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.13e-05	0.000936	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.1e-05	0.000923	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—CD36—dilated cardiomyopathy	2.09e-05	0.00092	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	2.03e-05	0.000895	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—RAC1—dilated cardiomyopathy	1.97e-05	0.000867	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.95e-05	0.00086	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	1.91e-05	0.000841	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.9e-05	0.000837	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—RAC1—dilated cardiomyopathy	1.9e-05	0.000834	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—AGT—dilated cardiomyopathy	1.81e-05	0.000797	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GPX1—dilated cardiomyopathy	1.78e-05	0.000783	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—CD36—dilated cardiomyopathy	1.73e-05	0.000763	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	1.73e-05	0.000761	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.71e-05	0.000754	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	1.71e-05	0.000753	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	1.63e-05	0.000717	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GPX1—dilated cardiomyopathy	1.56e-05	0.000687	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—AGT—dilated cardiomyopathy	1.56e-05	0.000687	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—CD36—dilated cardiomyopathy	1.52e-05	0.000669	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.46e-05	0.000642	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—AGT—dilated cardiomyopathy	1.37e-05	0.000603	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—RAF1—dilated cardiomyopathy	1.31e-05	0.000575	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—RAF1—dilated cardiomyopathy	1.26e-05	0.000553	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.13e-05	0.000497	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	9.9e-06	0.000436	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GPX1—dilated cardiomyopathy	8.7e-06	0.000383	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—EGFR—dilated cardiomyopathy	8.62e-06	0.000379	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CD36—dilated cardiomyopathy	8.47e-06	0.000373	CbGpPWpGaD
Mirabegron—ALB—Metabolism—AGT—dilated cardiomyopathy	7.63e-06	0.000336	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	7.62e-06	0.000335	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CD36—dilated cardiomyopathy	7.42e-06	0.000327	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	7.18e-06	0.000316	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	6.99e-06	0.000308	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—AGT—dilated cardiomyopathy	6.68e-06	0.000294	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	6.3e-06	0.000277	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	4.7e-06	0.000207	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	4.57e-06	0.000201	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	4.12e-06	0.000181	CbGpPWpGaD
